Kolon Life Science Inc (102940)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Kolon Life Science Inc (102940) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012296
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kolon Life Science Inc (KLS) carries out research and development, manufacture and commercialization of pharmaceutical products and active pharmaceutical ingredients (APIs). It develops innovative cell and gene therapeutics. The company’s lead product is Invossa, first cell-mediated gene therapy for osteoarthritis. KLS’ product portfolio includes biopharmaceuticals, APIs, antimicrobials and water treatment solutions. Its technology platform produces and utilizes protein for human body by performing gene manipulation and cell culturing technology. The company’s cell-mediated gene therapies are used in degenerative diseases. It offers anti-bacterial agents for cosmetic, paint and other industries and water treatment agents. KLS is headquartered in Gwachun-si, Gyunggi-do, South Korea.

Kolon Life Science Inc (102940) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kolon Life Science Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Kolon Life Science Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Kolon Life Science Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Kolon Life Science Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Kolon Life Science Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Kolon Life Science Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Mundipharma Enters into Agreement with Kolon Life Science 10
Licensing Agreements 11
Mitsubishi Tanabe Pharma Enters into Licensing Agreement with Kolon Life Science 11
Equity Offering 12
Kolon Life Science Raises USD98.6 Million in Rights Offering of Shares 12
Debt Offering 13
Kolon Life Science Completes Public Offering Of Bonds For US$28 Million 13
Kolon Life Science Inc – Key Competitors 14
Kolon Life Science Inc – Key Employees 15
Kolon Life Science Inc – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Recent Developments 17
Other Significant Developments 17
Dec 20, 2016: BioLife Solutions Executes 10 Year Supply Agreement with TissueGene for CryoStor Use in Invossa Osteoarthritis Cell-Mediated Gene Therapy 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Kolon Life Science Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Kolon Life Science Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Kolon Life Science Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Kolon Life Science Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Kolon Life Science Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Kolon Life Science Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Mundipharma Enters into Agreement with Kolon Life Science 10
Mitsubishi Tanabe Pharma Enters into Licensing Agreement with Kolon Life Science 11
Kolon Life Science Raises USD98.6 Million in Rights Offering of Shares 12
Kolon Life Science Completes Public Offering Of Bonds For US$28 Million 13
Kolon Life Science Inc, Key Competitors 14
Kolon Life Science Inc, Key Employees 15
Kolon Life Science Inc, Other Locations 16

★海外企業調査レポート[Kolon Life Science Inc (102940)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kimbell Royalty Partners LP (KRP):石油・ガス:M&Aディール及び事業提携情報
    Summary Kimbell Royalty Partners LP (KRP), is an oil and gas company that owns and acquires mineral and royalty interests in oil and natural gas properties throughout the US. The company has interests in the Permian Basin, Eagle Ford, Bakken Shale, San Juan Basin, Mid-Continent, East Texas, Barnett …
  • The Kansai Electric Power Co Inc (9503):電力:M&Aディール及び事業提携情報
    Summary The Kansai Electric Power Co Inc (KEPCo) is an integrated power utility. It produces and supplies electricity and thermal energy; and procures and sells natural gas. The company generates electricity using natural gas, nuclear, coal, oil, wind, hydro, and solar sources. Through long, medium, …
  • DNAtrix Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary DNAtrix Inc (DNAtrix) is an independent clinical stage, biotechnology company that focuses on the development of oncolytic immunotherapies for cancer. The company’s portfolio of pipeline products includes DNX-2401, a modified common cold virus that targets and kills cancer cells selectively; …
  • Sogefi S.p.A:企業の戦略・SWOT・財務情報
    Sogefi S.p.A - Strategy, SWOT and Corporate Finance Report Summary Sogefi S.p.A - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Exosome Diagnostics Inc:企業の製品パイプライン分析2018
    Summary Exosome Diagnostics Inc (Exosome Diagnostics) is a provider of diagnostic solutions. The company develops, designs, manufactures and markets biofluid-based molecular diagnostic tests and products for use in personalized medicine. Exosome Diagnostics’ services comprise miRNA profiling, mRNA p …
  • Infratil Ltd (IFT)-エネルギー分野:企業M&A・提携分析
    Summary Infratil Limited (Infratil) is involved in providing energy, transportation and infrastructure services. The company operates through trustpower, Australian energy, direct connect, Perth energy, Tilt Renewables, Wellington Airport, NZ bus, snapper, infratil property, Metlifecare, RetireAustr …
  • Kaiser Foundation Health Plan of Washington:企業の戦略的SWOT分析
    Kaiser Foundation Health Plan of Washington - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors a …
  • PT Bank CIMB Niaga Tbk (BNGA):企業の財務・戦略的SWOT分析
    PT Bank CIMB Niaga Tbk (BNGA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Faron Pharmaceuticals Oy (FARN):製薬・医療:M&Aディール及び事業提携情報
    Summary Faron Pharmaceuticals Oy (Faron) is a clinical stage biopharmaceutical company that conducts clinical stage drug discovery and development. The company's pipeline products focus on cute organ traumas, vascular damage and cancer immunotherapy. It offers Traumakine, that helps to prevent vascu …
  • Statoil ASA (STL)-石油・ガス分野:企業M&A・提携分析
    Summary Statoil ASA (Statoil) is an independent upstream oil and gas company. The company explores for, develops and produces oil and gas from its assets across the world, and trades crude oil and natural gas. The company operates assets in Norwegian Continental Shelf (NCS), which includes the North …
  • Avalon Oil & Gas Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Avalon Oil & Gas Inc (Avalon), formerly Snow Runner (USA) Inc is an oil and gas company that develops and operates crude oil and natural gas properties. The company acquires, produces and develops oil and natural gas reserves. It offers reservoir maintenance and technologies to produce portf …
  • Levi Strauss & Co.:企業の戦略・SWOT・財務情報
    Levi Strauss & Co. - Strategy, SWOT and Corporate Finance Report Summary Levi Strauss & Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Sanchez Energy Corp (SN):石油・ガス:M&Aディール及び事業提携情報
    Summary Sanchez Energy Corp (Sanchez) is an independent exploration and production company that acquires and develops unconventional oil and natural gas resources. The company operates in the horizontal development of resources from the Eagle Ford Shale in South Texas. It also holds an undeveloped a …
  • Open Text Corporation (OTEX):企業の財務・戦略的SWOT分析
    Open Text Corporation (OTEX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Tasly Pharmaceutical Group Co Ltd (600535):企業の財務・戦略的SWOT分析
    Tasly Pharmaceutical Group Co Ltd (600535) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Imvescor Restaurant Group Inc:戦略・SWOT・企業財務分析
    Imvescor Restaurant Group Inc - Strategy, SWOT and Corporate Finance Report Summary Imvescor Restaurant Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Claverack Rural Electric Cooperative Inc:企業の戦略的SWOT分析
    Claverack Rural Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Original BioMedicals Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Original BioMedicals Co Ltd (OBM) is a biotechnology company that develops new drug delivering systems to deal with unmet clinical needs in the therapeutic areas of oncology, hematology and immunology. The company’s pipeline products include A01, A02 and P01. Its pipeline product OBM-A01 is …
  • EchoStar Corporation:企業の戦略・SWOT・財務情報
    EchoStar Corporation - Strategy, SWOT and Corporate Finance Report Summary EchoStar Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • ArQule Inc (ARQL)-製薬・医療分野:企業M&A・提携分析
    Summary ArQule Inc (ArQule) is a development stage clinical biotechnology company. It carries out discovery and development of next-generation, small molecule therapeutics for the treatment of various types of cancer. ArQule develops its oncology product candidates through novel approaches including …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆